Outset Medical, Inc. and U.S. Renal Care announced a multi-year agreement to help accelerate home hemodialysis in the U.S. Studies show patients with end-stage kidney disease (ESKD) are healthier mentally and physically dialyzing at home, more likely to be employed and maintain more control of their daily activities. Yet, just 3% of the ESKD population currently performs home hemodialysis, in large part due to historically complicated systems that made it too difficult to undertake or sustain. Under the multi-year agreement, U.S. Renal Care can utilize Outset?s Tablo Hemodialysis System as a home dialysis option throughout the 33 states in which it provides care.

Patients dialyzing with Tablo report that the system is easy to learn and operate in their home. Expanding treatment options in the communities served by U.S. Renal Care will aid in meeting the growing demand of dialysis patients seeking treatment at home. Tablo, is indicated for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers.

Requiring just access to tap water and a standard electrical outlet, Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone.